Alyeska Investment Group
LUCD icon

Alyeska Investment Group’s Lucid Diagnostics LUCD Stock Holding History

Alyeska Investment Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,383,116
Closed -$1.4M – 670
2025
Q3 		$1.4M Buy
1,383,116
+644,839
+87% +$704K ﹤0.01% 527
2025
Q2 		$849K Sell
738,277
-1,149,566
-61% -$1.48M ﹤0.01% 511
2025
Q1 		$2.81M Buy
+1,887,843
New +$2.27M 0.01% 401

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group's LUCD Position: Q4 2025 in Review

Alyeska Investment Group sold out of Lucid Diagnostics (LUCD) in Q4 2025, closing a stake of 1,383,116 shares — an estimated $1.4M sold.

Alyeska Investment Group first reported a position in LUCD in Q1 2025 and held it in 3 quarters. The position peaked at $2.81M in Q1 2025. 89 funds tracked by Wall St. Rank hold LUCD as of Q4 2025.

  • Alyeska Investment Group reported no remaining Lucid Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 1,383,116 Lucid Diagnostics shares in Q4 2025, an estimated $1.4M.
  • Alyeska Investment Group first reported a position in Lucid Diagnostics in Q1 2025 and held it in 3 quarters.
  • Alyeska Investment Group's Lucid Diagnostics position peaked at $2.81M in Q1 2025.
  • 89 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.